2-butyl-4,5-dihydro-4-oxo-3H-imidazo<4,5-c>pyridine | 133052-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-butyl-4,5-dihydro-4-oxo-3H-imidazo<4,5-c>pyridine
• 英文别名: 2-Butyl-3h-imidazo[4,5-c]pyridin-4(5h)-one；2-butyl-1,5-dihydroimidazo[4,5-c]pyridin-4-one
• CAS: 133052-28-5
• 化学式: C₁₀H₁₃N₃O
• 分子量: 191.233
• InChiKey: DQNFMKNGBGWUDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-butyl-4,5-dihydro-4-oxo-3H-imidazo<4,5-c>pyridine 在 potassium tert-butylate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 2-[4-[(5-benzyl-2-butyl-4-oxoimidazo[4,5-c]pyridin-3-yl)methyl]phenyl]-N-tert-butylbenzenesulfonamide
  参考文献：
  名称：

  Novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines. Potent angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes

  摘要：

  The synthesis and pharmacological activity of balanced high affinity non-peptide angiotensin II antagonists of the AT(1) and AT(2) subtype receptors have been presented. A series of previously prepared AT(1) selective 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines were modified at four different positions in order to increase the AT(2) binding affinity by maintaining the nanomolar activity for the AT(1) receptor. The targeted AT(2)/AT(1) IC50 binding ratio of similar to 1 was achieved with a number of compounds possessing a small alkyl chain at C-2, different acetamide groups at N-5 and a 3-fluoro and 2'-carboxamidosulfonyl substituent at the biphenylmethyl moiety. These modifications led to analogue 12s, which exhibited an AT(2)/AT(1) ratio of 0.74, a subnanomolar AT(1) antagonistic potency (0.18 nM) and a high metabolic stability in rat and monkey liver microsomes in vitro. After oral administration of 3 mg/kg to cynomolgus monkeys, EMD 90423 (potassium salt of 12s) demonstrated good efficacy and a long duration of action as an antihypertensive agent.

  DOI：

  10.1016/s0223-5234(97)84011-1
• 作为产物：
  描述：

  2-氯-3,4-二氨基吡啶 在 盐酸 、 PPA 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 41.0h， 生成 2-butyl-4,5-dihydro-4-oxo-3H-imidazo<4,5-c>pyridine
  参考文献：
  名称：

  非肽血管紧张素II受体拮抗剂：一系列新型4,5-二氢-4-氧代-3H-咪唑并[4,5-c]吡啶衍生物的合成和生物活性。

  摘要：

  通过几种合成途径制备了一系列含有2,3,5-三取代的4,5-二氢-4-氧代-3H-咪唑并[4,5-c]吡啶的新型非肽血管紧张素II受体拮抗剂。它们对血管紧张素II受体的亲和力是在结合试验和分离器官试验中建立的。具有亲和力和效能在纳摩尔范围内的优选化合物是在C-2处具有小的烷基基团和在N-3处具有（甲基联苯基基）四唑部分的分子。N-5位置的变异可调节活性。在N-5处被各种苄基取代，所产生的衍生物的体外效价在纳摩尔范围内，在这些测定中与氯沙坦相当。用乙酸酯或特别是乙酰胺代替N-5氢，使分子具有增强的活性。最有效的是2-丁基-4,5-二氢-4-氧代-3-[[2'-（1H-四唑-5-基）-4-联苯基]]甲基] -3H-咪唑并[4,5- c]吡啶-5-（N，N-二乙基乙酰胺）（14u），在体外优于L-158,809。选择了两个原型作为其钾盐作为抗高血压药物进行体内测试。静脉给药时，化合物14a（EMD

  DOI：

  10.1021/jm00037a014

文献信息

• N-aryl heterocycles via coupling reactions with arylboronic acids
  作者：Werner W.K.R. Mederski、Marina Lefort、Martina Germann、Dieter Kux

  DOI：10.1016/s0040-4020(99)00752-8

  日期：1999.10

  procedure leads to N5-arylated imidazo[4,5-c]pyridin-4-ones, precursors of potent factor Xa inhibitors. In addition, the synthesis of N-aryl substituted pyrrole- and indole-2-carboxylic acid esters is described. In the indole series this procedure offers a flexible entry in the synthesis of different 1,3-diaryl-2-carboxyindoles.

  根据Chan和Lam描述的方法，可以将具有部分2-吡啶酮结构或3-吡啶酮酮的化合物用苯基硼酸选择性地N-芳基化。该过程产生了N 5芳基咪唑并[4,5-c]吡啶-4-酮，它们是有效的Xa因子抑制剂的前体。另外，描述了N-芳基取代的吡咯-和吲哚-2-羧酸酯的合成。在吲哚系列中，该方法为合成不同的1,3-二芳基-2-羧基吲哚提供了灵活的途径。
• Benzofuranderivate als Angiotensin II Antagonisten
  申请人：MERCK PATENT GmbH

  公开号：EP0546449A2

  公开（公告）日：1993-06-16

  Neue Benzofurane der Formel I worin R den Rest bedeutet und R1 bis R3 sowie -A-B-C-D- die in Anspruch 1 angegebene Bedeutung haben, sowie deren Salze zeigen angiotensin II-antagonistische Eigenschaften und können zur Behandlung von Hypertension, Aldosteronismus und Herzinsuffizienz verwendet werden.

  式 I 的新苯并呋喃 其中 R 代表基团 和 R1 至 R3 和 -A-B-C-D-具有权利要求 1 所述的含义，它们的盐类具有血管紧张素 II 拮抗特性，可用于治疗高血压、醛固酮增多症和心力衰竭。
• [EN] BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] BIPHÉNYLE SULFONAMIDES EN TANT QUE DOUBLES ANTAGONISTES DU RÉCEPTEUR D'ANGIOTENSINE ET D'ENDOTHÉLINE
  申请人：LIGAND PHARM INC

  公开号：WO2009158309A2

  公开（公告）日：2009-12-30

  The present invention provides novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists useful in the treatment of conditions such as hypertension and other diseases.
• Novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines. Potent angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes
  作者：W.W.K.R. Mederski、D Dorsch、M Osswald、H Schwartz、N Beier、M Christadler、K.O. Minck、P Schelling、C.J. Schmitges

  DOI：10.1016/s0223-5234(97)84011-1

  日期：1997.6

  The synthesis and pharmacological activity of balanced high affinity non-peptide angiotensin II antagonists of the AT(1) and AT(2) subtype receptors have been presented. A series of previously prepared AT(1) selective 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines were modified at four different positions in order to increase the AT(2) binding affinity by maintaining the nanomolar activity for the AT(1) receptor. The targeted AT(2)/AT(1) IC50 binding ratio of similar to 1 was achieved with a number of compounds possessing a small alkyl chain at C-2, different acetamide groups at N-5 and a 3-fluoro and 2'-carboxamidosulfonyl substituent at the biphenylmethyl moiety. These modifications led to analogue 12s, which exhibited an AT(2)/AT(1) ratio of 0.74, a subnanomolar AT(1) antagonistic potency (0.18 nM) and a high metabolic stability in rat and monkey liver microsomes in vitro. After oral administration of 3 mg/kg to cynomolgus monkeys, EMD 90423 (potassium salt of 12s) demonstrated good efficacy and a long duration of action as an antihypertensive agent.
• Non-Peptide Angiotensin II Receptor Antagonists: Synthesis and Biological Activity of a Series of Novel 4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridine Derivatives
  作者：Werner W. K. R. Mederski、Dieter Dorsch、Heinz-Hermann Bokel、Norbert Beier、Ingeborg Lues、Pierre Schelling

  DOI：10.1021/jm00037a014

  日期：1994.5

  A series of novel non-peptide angiotensin II receptor antagonists containing a 2,3,5-trisubstituted 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine was prepared via several synthetic routes. Their affinity for angiotensin II receptors was established in a binding assay experiment and in an isolated-organ test. Molecules with small alkyl groups at C-2 and the (methylbiphenylyl)tetrazole moiety at N-3 were

  通过几种合成途径制备了一系列含有2,3,5-三取代的4,5-二氢-4-氧代-3H-咪唑并[4,5-c]吡啶的新型非肽血管紧张素II受体拮抗剂。它们对血管紧张素II受体的亲和力是在结合试验和分离器官试验中建立的。具有亲和力和效能在纳摩尔范围内的优选化合物是在C-2处具有小的烷基基团和在N-3处具有（甲基联苯基基）四唑部分的分子。N-5位置的变异可调节活性。在N-5处被各种苄基取代，所产生的衍生物的体外效价在纳摩尔范围内，在这些测定中与氯沙坦相当。用乙酸酯或特别是乙酰胺代替N-5氢，使分子具有增强的活性。最有效的是2-丁基-4,5-二氢-4-氧代-3-[[2'-（1H-四唑-5-基）-4-联苯基]]甲基] -3H-咪唑并[4,5- c]吡啶-5-（N，N-二乙基乙酰胺）（14u），在体外优于L-158,809。选择了两个原型作为其钾盐作为抗高血压药物进行体内测试。静脉给药时，化合物14a（EMD